UNSPSC 51332514: Trifluperidol

This classification denotes an antipsychotic agent with the molecular formula C22H23F4NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8869Q7R8I, chemically known as 4-fluoro-4-(4-hydroxy-4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidino)butyrophenone but generally known as trifluperidol, which bears US NIH Compound Identifier 5567. European Medicines Agency schedules Trifluperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11289MIG.

UNSPSC 51332514 Trifluperidol (Commodity) covers pharmaceutical products, though the recent state and local solicitations tagged under this code reflect broader procurement of naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products rather than trifluperidol specifically. The code captures what state health agencies, county health departments, and cooperative purchasing alliances actually buy — emergency response medications, harm-reduction supplies, and generic pharmaceutical inventory for public health facilities and safety programs. Issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering for participating state and local government facilities including Oregon). Recent work ranges from direct naloxone procurement for quarterly delivery to community health buildings, to exploratory requests for information on direct-to-manufacturer prescription programs, to large-scale RFPs for generic pharmaceuticals distributed through authorized wholesalers.

Geographic activity centers on Florida, Texas, and Minnesota with multistate reach through cooperative vehicles. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring electronic bid submission and E-Verify compliance on a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to gather market intelligence on direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels before issuing a formal RFP. The Minnesota Department of Administration's Office of State Procurement issued an RFP through MMCAP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, with awards effective July 1, 2026, requiring cGMP and Drug Supply Chain Security Act compliance, relationships with at least two of three authorized wholesalers, and pricing weighted 75 percent on competitiveness with administrative fees of 3 percent on all purchases.